AARDS' Dr. Norman B. Gaylis Pioneers New Rheumatoid Arthritis Treatment in the US

AARDS Research (Arthritis & Rheumatic Specialties) is making headlines as it celebrates a significant achievement in the fight against rheumatoid arthritis. Dr. Norman B. Gaylis, the Medical Director of AARDS, has gained recognition as the first physician in the United States to utilize the FDA-approved SetPoint System, a novel device aimed at treating the debilitating condition. This breakthrough is expected to provide hope to over 1.5 million Americans affected by rheumatoid arthritis.

The SetPoint System: A Revolutionary Advancement

The SetPoint System marks a pivotal development in bioelectronics, offering a fresh approach to treating rheumatoid arthritis. Unlike traditional methods that predominantly rely on medications, this device operates by stimulating the vagus nerve, located in the neck, to alleviate inflammation. Patients only need to undergo a simple surgical procedure for implant placement; afterward, the device administers brief daily stimulation that helps reset the immune system, presenting a remarkable alternative to conventional therapeutic options.

Dr. Gaylis, who leads AARDS in clinical research, has been deeply involved with this technology since its inaugural treatments began seven years ago. His team initially treated two patients whose cases demonstrated substantial improvement, laying the groundwork for expanded clinical trials. The device maintains an excellent safety profile with no adverse events reported, which is particularly encouraging since standard RA medications often compromise the immune system, potentially increasing the risk for patients.

Real Stories, Real Success

One of the early recipients of the SetPoint device is Gerline Brutus from Fort Lauderdale. After struggling with severe rheumatoid arthritis for several years, Gerline began her treatment at age 48. Before the device, she found herself struggling with everyday tasks, requiring assistance for errands and housework. Now, at 55, she celebrates her regained independence, stating, "I was in so much pain before that I had trouble getting out of bed... now I can do everything on my own and it's amazing!" Her story encapsulates the potential of the SetPoint System to restore quality of life to those battling debilitating symptoms.

Dr. Gaylis expressed excitement about the FDA's endorsement of the technology, stating, "We are thrilled to see the FDA recognize the efficacy of this technology... our clinic was selected as the first to treat patients with the SetPoint implant." His commitment to innovative treatment solutions has positioned AARDS as a leader in conducting crucial research that benefits underserved patient populations.

Looking Beyond Rheumatoid Arthritis

The implications of the SetPoint System extend beyond just rheumatoid arthritis. Following its success, clinical studies are underway to explore its application in treating other autoimmune conditions including lupus, Crohn's disease, multiple sclerosis, and inflammatory bowel disease. This reflects a significant opportunity for a new class of bioelectronic medicine therapies to emerge, potentially transforming the landscape of autoimmune disorder treatment.

AARDS' Commitment to Innovation

With over 40 years of experience, AARDS has established a reputation as a front-runner in medical innovation and research. The institution has participated in more than 150 clinical trials, including those targeting complex chronic diseases and the long effects of COVID-19. The recent success with the SetPoint device not only reinforces their leadership in clinical research but also underscores their unwavering commitment to placing patients' needs at the forefront of medical advancement.

For more information on AARDS’ groundbreaking work or to learn about the SetPoint System, visit www.rheum-care.com. For interviews with Dr. Norman B. Gaylis or patients treated with the device, contact Rhonda Price at [email protected].

Meet Dr. Norman B. Gaylis

Dr. Norman B. Gaylis, M.D., F.A.C.P., M.A.C.R. is a highly esteemed expert in the field of arthritis and autoimmune disorders. Based in Miami, Florida, he has been at the helm of groundbreaking research, frequently presenting his findings at international medical conferences and has authored numerous scholarly articles. A member of the American College of Rheumatology board, Dr. Gaylis is dedicated to fostering research in the clinical practice of rheumatology, epitomizing excellence and leadership within his field.